Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Pharmacokinetic Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

Trial Profile

An Open-label, Multicenter, Pharmacokinetic Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs EB 8018 (Primary)
  • Indications Crohn's disease
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Enterome
  • Most Recent Events

    • 09 Nov 2018 Planned End Date changed from 31 Dec 2018 to 28 Feb 2019.
    • 09 Nov 2018 Planned primary completion date changed from 30 Oct 2018 to 31 Jan 2019.
    • 23 Oct 2018 According to an Enterome media release, Enterome has entered into a global licensing, co-development and co-promotion agreement with Takeda which covers EB8018 in patients with Crohns disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top